China · Delayed Price · Currency is CNY Cathay Biotech Statistics
Total Valuation
Cathay Biotech has a market cap or net worth of CNY 28.13 billion. The enterprise value is 24.07 billion.
| Market Cap | 28.13B |
| Enterprise Value | 24.07B |
Important Dates
The last earnings date was Saturday, October 31, 2026.
| Earnings Date | Oct 31, 2026 |
| Ex-Dividend Date | Jul 29, 2026 |
Share Statistics
Cathay Biotech has 720.66 million shares outstanding. The number of shares has increased by 11.26% in one year.
| Current Share Class | 720.66M |
| Shares Outstanding | 720.66M |
| Shares Change (YoY) | +11.26% |
| Shares Change (QoQ) | +2.65% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 14.21% |
| Float | 307.64M |
Valuation Ratios
The trailing PE ratio is 44.16 and the forward PE ratio is 34.58.
| PE Ratio | 44.16 |
| Forward PE | 34.58 |
| PS Ratio | 7.84 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 37.62 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 37.79 |
| EV / Sales | 6.71 |
| EV / EBITDA | 25.86 |
| EV / EBIT | 39.02 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.71 |
| Quick Ratio | 4.60 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.96 |
| Debt / FCF | n/a |
| Interest Coverage | 6,429.57 |
Financial Efficiency
Return on equity (ROE) is 2.93% and return on invested capital (ROIC) is 3.96%.
| Return on Equity (ROE) | 2.93% |
| Return on Assets (ROA) | 1.60% |
| Return on Invested Capital (ROIC) | 3.96% |
| Return on Capital Employed (ROCE) | 2.74% |
| Weighted Average Cost of Capital (WACC) | 6.78% |
| Revenue Per Employee | 1.95M |
| Profits Per Employee | 345,446 |
| Employee Count | 1,844 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 1.76 |
Taxes
In the past 12 months, Cathay Biotech has paid 101.21 million in taxes.
| Income Tax | 101.21M |
| Effective Tax Rate | 13.84% |
Stock Price Statistics
The stock price has decreased by -18.87% in the last 52 weeks. The beta is 0.50, so Cathay Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -18.87% |
| 50-Day Moving Average | 39.05 |
| 200-Day Moving Average | 46.58 |
| Relative Strength Index (RSI) | 55.92 |
| Average Volume (20 Days) | 3,761,239 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cathay Biotech had revenue of CNY 3.59 billion and earned 637.00 million in profits. Earnings per share was 0.88.
| Revenue | 3.59B |
| Gross Profit | 1.09B |
| Operating Income | 616.84M |
| Pretax Income | 731.49M |
| Net Income | 637.00M |
| EBITDA | 919.33M |
| EBIT | 616.84M |
| Earnings Per Share (EPS) | 0.88 |
Balance Sheet
The company has 8.77 billion in cash and 890.83 million in debt, with a net cash position of 7.88 billion or 10.94 per share.
| Cash & Cash Equivalents | 8.77B |
| Total Debt | 890.83M |
| Net Cash | 7.88B |
| Net Cash Per Share | 10.94 |
| Equity (Book Value) | 21.75B |
| Book Value Per Share | 24.48 |
| Working Capital | 9.72B |
Cash Flow
In the last 12 months, operating cash flow was 747.64 million and capital expenditures -1.03 billion, giving a free cash flow of -285.43 million.
| Operating Cash Flow | 747.64M |
| Capital Expenditures | -1.03B |
| Depreciation & Amortization | 302.49M |
| Net Borrowing | 611.12M |
| Free Cash Flow | -285.43M |
| FCF Per Share | -0.40 |
Margins
Gross margin is 30.41%, with operating and profit margins of 17.19% and 17.75%.
| Gross Margin | 30.41% |
| Operating Margin | 17.19% |
| Pretax Margin | 20.39% |
| Profit Margin | 17.75% |
| EBITDA Margin | 25.62% |
| EBIT Margin | 17.19% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | 0.45 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | 12.50% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 53.93% |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.26% |
| Shareholder Yield | -10.10% |
| Earnings Yield | 2.26% |
| FCF Yield | -1.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Cathay Biotech is 55.09, which is 41.15% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 55.09 |
| Price Target Difference | 41.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 14.10% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on July 20, 2022. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 20, 2022 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |